Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -19.72% and +14.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?